Vanguard Group Inc Cyclo Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 446,573 shares of CYTH stock, worth $339,395. This represents 0.0% of its overall portfolio holdings.

Number of Shares

446,573

Previous 396,658 12.58%

Holding current value

$339,395

Previous $551,000 2.9%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.16 - $1.53 $57,901 - $76,369	49,915 Added 12.58%	446,573 $567,000
Q1 2024 May 10, 2024	BUY	$1.39 - $1.9 $57,594 - $78,726	41,435 Added 11.66%	396,658 $551,000
Q4 2023 Feb 14, 2024	BUY	$0.93 - $1.88 $68,072 - $137,608	73,196 Added 25.95%	355,223 $564,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $1.88 $27,279 - $40,702	21,650 Added 8.31%	282,027 $400,000
Q2 2023 Aug 14, 2023	BUY	$0.67 - $2.3 $4,351 - $14,938	6,495 Added 2.56%	260,377 $413,000
Q4 2022 Feb 10, 2023	BUY	$0.95 - $2.13 $111 - $249	117 Added 0.05%	253,882 $360,000
Q2 2022 Aug 12, 2022	SELL	$1.97 - $3.21 $2,561 - $4,173	-1,300 Reduced 0.51%	253,765 $500,000
Q1 2022 May 13, 2022	BUY	$2.62 - $4.51 $2,001 - $3,445	764 Added 0.3%	255,065 $808,000
Q4 2021 Feb 14, 2022	BUY	$3.47 - $7.34 $286,691 - $606,430	82,620 Added 48.12%	254,301 $948,000
Q3 2021 Nov 12, 2021	BUY	$6.21 - $10.04 $125,075 - $202,215	20,141 Added 13.29%	171,681 $1.16 Million
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.85 $997,133 - $1.64 Million	151,540 New	151,540 $1.55 Million

Others Institutions Holding CYTH

# of Institutions

Shares Held

2.24M

Call Options Held

Put Options Held

View Full List

About Cyclo Therapeutics, Inc.

Ticker CYTH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 8,439,440
Market Cap $6.41M
Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...

More about CYTH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Cyclo Therapeutics, Inc. Transaction History